Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: An overview

Neurobiology of Aging

Volumn 32, Issue SUPPL. 1, 2011, Pages

  Morris, John C ^a   Selkoe, Dennis J ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN;

ALZHEIMER DISEASE; ASYMPTOMATIC DISEASE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; EDITORIAL; HEALTH CARE COST; HUMAN; MOLECULAR DIAGNOSIS; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RESEARCH SUBJECT; TREATMENT RESPONSE;

EID: 80955166367     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.09.005     Document Type: Article

References (18)

1. Aisen P.S. Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol. Aging 2011, 32:S64-S66.
2. Albert M.S. Changes in cognition. Neurobiol. Aging 2011, 32:S58-S63.
3. Generation Alzheimers: the Defining Disease of the Baby Boomers [Pamphlet] 2011, Alzheimer's Association, Alzheimer's Association, Chicago.
4. Bateman R.J., Aisen P.S., De Strooper B., Fox N.C., Lemere C.A., Ringman J.M., Salloway S., Sperling R.A., Windisch M., Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther 2011, 3:1-13.
5. Bateman R.J., Wen G., Morris J.C., Holtzman D.M. Fluctuations of CSF amyloid-B levels; implications for a diagnostic and therapeutic biomarker. Neurology 2007, 68:666.
6. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L., Jessen F., Hoessler Y.C., Sanhai W.R., Zetterberg H., Woodcock J., Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov 2010, 9:560-574.
7. Holtzman D.M. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol. Aging 2011, 32:S4-S9.
8. Jack C.R. Alliance for Aging Research AD Biomarkers Work Group: structural MRI. Neurobiol. Aging 2011, 32:S48-S57.
9. Klunk W.E. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol. Aging 2011, xx. xx-xx.
10. Mayeux R., Schupf N. Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants. Neurobiol. Aging 2011, xx. xx-xx.
11. Mckhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers & Dement 2011, 7:263-269.
12. Pepe M.S., Feng Z., Janes H., Bossuyt P.M., Potter J.D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl. Cancer Inst 2008, 100:1432-1438.
13. Perrin R.J., Fagan A.M., Holtzman D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009, 461:916-922.
14. Reiman E.M. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol. Aging 2011, 32:S44-S47. Alzheimer's Disease Biomarkers Working Group for the Alliance for Aging Research.
15. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., de Llano S.R.M., Liu E., Koller M., Gregg K.M., Schenk D., Black R., Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-B load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet 2010, 9:363-372.
16. Siemers E., Demattos R.B., May P.C., Dean R.A. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. Biomark. Med 2010, 4:81-89.
17. Snider B.J., Fagan A.M., Roe C., Shah A.R., Grant E.A., Xiong C., Morris J.C., Holtzman D.M. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch. Neurol 2009, 66:638-645.
18. Sperling R. The potential of functional MRI as a biomarker in early Alzheimer's disease. Neurobiol. Aging 2011, 32:S37-S43.